Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer : Results of a propensity-matched analysis of the OnCovid registry
Mostaghim, Anahita (University of Washington. Department of Medicine)
Minkove, Samuel (Critical Care Medicine Department. National Institutes of Health Clinical Center)
Aguilar Company, Juan (Hospital Universitari Vall d'Hebron)
Ruiz-Camps, Isabel (Hospital Universitari Vall d'Hebron)
Eremiev, Simeón (Hospital Universitari Vall d'Hebron)
Dettorre, Gino M. (Department of Internal Medicine. Washington University School of Medicine)
Fox, Laura (Vall d'Hebron Institut d'Oncologia)
Tondini, Carlo (ASST Papa Giovanni XXIII (Bergamo, Itàlia))
Brunet, Joan (Hospital Universitari de Girona Doctor Josep Trueta)
Carmona-Garcia, M. Carmen (Hospital Universitari de Girona Doctor Josep Trueta)
Lambertini, Matteo (Department of Internal Medicine and Medical Specialties (DiMI). School of Medicine. University of Genova)
Bower, Mark (Chelsea and Westminster Hospital (Londres, Regne Unit))
Newsom-Davis, Thomas (Chelsea and Westminster Hospital (Londres, Regne Unit))
Sharkey, Rachel (Chelsea and Westminster Hospital (Londres, Regne Unit))
Pria, Allesia Dalla (Chelsea and Westminster Hospital (Londres, Regne Unit))
Rossi, Maura (Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo)
Plaja, Andrea (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Salazar, Ramon (Department of Medical Oncology. ICO L'Hospitalet. Oncobell Program (IDIBELL). CIBERONC. Hospitalet de Llobregat)
Sureda, Anna (Institut d'Investigació Biomèdica de Bellvitge)
Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Michalarea, Vasiliki (Guy's and St Thomas' NHS Foundation Trust (Regne Unit))
Van Hemelrijck, Mieke (King's College London. School of Cancer and Pharmaceutical Sciences)
Sita-Lumsden, Ailsa (Guy's and St Thomas' NHS Foundation Trust (Regne Unit))
Bertuzzi, Alexia (Medical Oncology and Hematology Unit. Humanitas Cancer Center. IRCCS Humanitas Research Hospital)
Rimassa, Lorenza (Department of Biomedical Sciences. Humanitas University. Via Rita Levi Montalcini)
Rossi, Sabrina (Medical Oncology and Hematology Unit. Humanitas Cancer Center. IRCCS Humanitas Research Hospital)
Rizzo, Gianpiero (Fondazione IRCCS Policlinico San Matteo (Itàlia))
Pedrazzoli, Paolo (Department of Internal Medicine and Medical Therapy. University of Pavia)
Lee, Alvin J. (Cancer Division. University College London Hospital)
Murphy, Cian (Cancer Division. University College London Hospital)
Belessiotis, Katherine (University College London Hospital)
Diamantis, Nikolaos (Medical Oncology. Barts Health NHS Trust)
Mukherjee, Uma (Medical Oncology. Barts Health NHS Trust)
Pommeret, Fanny (Institut Gustave Roussy. University of Paris Saclay)
Stoclin, Annabelle (Department of Cancer Medicine. Institut Gustave Roussy. University of Paris Saclay)
Martinez-Vila, Clara (Fundació Althaia (Manresa))
Bruna, Riccardo (University of Piemonte Orientale and Ospedale Maggiore della Carità Hospital)
Gaidano, Gianluca (Division of Haematology. Department of Translational Medicine. University of Piemonte Orientale and Ospedale Maggiore della Carità Hospital)
D'avanzo, Francesca (University of Piemonte Orientale)
Gennari, Alessandra (University of Piemonte Orientale)
Athale, Janhavi (Mayo Clinic Arizona (Phoenix, Estats Units d'Amèrica))
Eichacker, Peter (Critical Care Medicine Department. National Institutes of Health Clinical Center)
Pinato, David James (Imperial College London. Department of Surgery & Cancer)
Torabi-Parizi, Parizad (Critical Care Medicine Department. Clinical Center and National Heart Lung and Blood Institute. National Institutes of Health)
Cortellini, Alessio (Medical Oncology. Fondazione Policlinico Universitario Campus Bio-Medico)

Data:	2024
Resum:	Objectives: To date, studies have not provided definitive answers regarding whether previous immune checkpoint inhibitor (ICI) treatment alters outcomes for cancer patients with COVID-19. Methods: The OnCovid registry (NCT04393974) was searched from February 27, 2020, to January 31, 2022, for patients who received systemic anti-cancer therapy in the 4 weeks before laboratory-confirmed COVID-19 diagnosis. Propensity-score matching using country, vaccination status, primary tumor type, sex, age, comorbidity burden, tumor stage, and remission status investigated differences in predefined clinical outcomes comparing those who had or had not received ICIs. Results: Of 3523 patients screened, 137 ICI-only and 1378 non-ICI met inclusion criteria. Before matching, ICI patients were older, male, enrolled at centers in Italy, and had histories of smoking, thoracic cancers, advanced cancer stages, and active malignancies (P ≤0. 02). After matching, there were 120 ICI and 322 non-ICI patients. ICI patients had no differences (odds ratio: 95% CI) in presenting COVID-19 symptoms (0. 69: 0. 37-1. 28), receipt of COVID-specific therapy (0. 88: 0. 54-1. 41), 14-day (0. 95: 0. 56-1. 61), or 28-day (0. 79: 0. 48-1. 29) mortalities. However, ICI patients required less COVID-19-related hospitalization (0. 37: 0. 21-0. 67) and oxygen therapy (0. 51: 0. 31-0. 83) and developed fewer complications (0. 57: 0. 36-0. 92). Conclusion: In this propensity-score matched analysis, previous ICI therapy did not worsen and potentially improved COVID-19 outcomes in patients with cancer.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	COVID-19 ; SARS-CoV-2 ; Malignancy ; Immunotherapy ; Checkpoint inhibitor
Publicat a:	International journal of infectious diseases, Vol. 139 (february 2024) , p. 13-20, ISSN 1878-3511

DOI: 10.1016/j.ijid.2023.11.021

8 p, 998.6 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats